Skip to main content
Fig. 7 | Cancer Nanotechnology

Fig. 7

From: A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation

Fig. 7

As/miR34aNPs inhibits the HCC progression after insufficient ablation in vivo. As/miR34aNP uptake by tumour cells was enhanced in the slightly acidic tumour microenvironment. This formulation could inhibit c-met expression to exert antitumour efficacy. GSDME cleavage is triggered by caspase-3 activation after treatment with As/miR34aNPs. GSDME-N is released into the membrane and mitochondria. Drug treatment stabilized GSDME-N and triggered Cyt-c release and then cleaved GSDME indirectly to form a loop

Back to article page